 Home > Medical News > Latest Medical News > Fuhong Hanlius' PD-1 inhibitor international multi-center phase III clinical study reaches the primary endpoint of OS

Fuhong Hanlius' PD-1 inhibitor international multi-center phase III clinical study reaches the primary endpoint of OS

 Last Update: 2021-12-30
 Source: Internet
 Author: User

Tags

multi purpose foam

monoclonal antibody naming

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 7th, Henlius Group announced that its self-developed innovative PD-1 inhibitor slulimumab combined with chemotherapy will be randomized for untreated extensive-stage small cell lung cancer (ES-SCLC).

The main purpose of this study is to study the effectiveness and safety of slulimumab combined with chemotherapy in ES-SCLC patients who have not received previous treatment

Note: The original text has been deleted

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

For the first-line treatment of small cell lung cancer, the international multi-center phase III clinical study of Fuhong Hanlius' PD-1 inhibitor, Slulimumab, reached the primary endpoint of OS

12-30

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Fuhong Hanlius' PD-1 inhibitor international multi-center phase III clinical study reaches the primary endpoint of OS

Related Articles

For the first-line treatment of small cell lung cancer, the international multi-center phase III clinical study of Fuhong Hanlius' PD-1 inhibitor, Slulimumab, reached the primary endpoint of OS